Tarsus Pharmaceuticals Inc
NASDAQ: TARS · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-05
Tarsus Pharmaceuticals Inc (TARS) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $2.39M | $58.32M | $171.97M | $178.91M | $227.86M | $265.49M | $376.99M | $562.16M |
| Cash & equivalents | $2.35M | $57.95M | $168.13M | $171.33M | $71.66M | $224.95M | $94.82M | $183.64M |
| Current assets | $2.38M | $58.03M | $170.66M | $175.95M | $225.38M | $256.13M | $356.70M | $522.78M |
| Total liabilities | $3.74M | $64.32M | $5.99M | $12.18M | $34.96M | $68.50M | $152.46M | $218.73M |
| Current liabilities | $179000.00 | $819000.00 | $5.39M | $11.48M | $15.43M | $36.94M | $80.61M | $135.69M |
| Long-term debt | — | — | — | — | $19.43M | $29.82M | $71.84M | $72.44M |
| Shareholder equity | $-1.35M | $-6.00M | $165.98M | $166.73M | $192.90M | $196.99M | $224.53M | $343.43M |
| Retained earnings | $-1.36M | $-6.03M | $-32.84M | $-46.67M | $-108.76M | $-244.66M | $-360.21M | $-426.63M |
| Accounts receivable | $4000.00 | $36000.00 | $20000.00 | $92000.00 | $3.58M | $17.71M | $48.06M | $87.11M |
| Inventory | — | $20000.00 | — | $175.68M | $4.76M | $3.11M | $2.62M | $4.37M |
| Goodwill | — | — | — | — | — | — | — | — |
Frequently asked questions
What is Tarsus Pharmaceuticals Inc's revenue?
Tarsus Pharmaceuticals Inc's trailing twelve-month revenue is $535.08M, and consensus projects about $1.58B by 2030. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is TARS?
In its most recent fiscal year, TARS ran a gross margin of 93.20%, an operating margin of -15.72%, and a net margin of -14.72%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does TARS generate?
TARS produced $-22.31M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is TARS's balance sheet healthy?
TARS holds $183.64M in cash and equivalents against $72.44M in long-term debt, on $343.43M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.